Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06094725 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
A Phase 1 study of Hepatic Impairment, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT06094725 is a Phase 1 study of Hepatic Impairment that has completed, run by Corcept Therapeutics. The registered enrollment target is 30 participants, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (17% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06094725, a Phase 1 study of Hepatic Impairment, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this multiple-dose, adaptive design study is to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of relacorilant relative to healthy matched control male and female subjects (Part 1).
Conditions Studied
Interventions
- DRUG Relacorilant
Study Locations (2)
Florida
- Clinical Pharmacology of Miami, LLC - Miami
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-01-06 |
| Est. Completion | 2020-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06094725
The ClinicalTrials.gov registry entry for NCT06094725 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (17% lower). The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatic Impairment appearing as the primary indexed condition, and to 1 intervention - of which Relacorilant is the first listed.
NCT06094725 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06094725 about?
NCT06094725 is a clinical study titled "A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant". The primary objective of this multiple-dose, adaptive design study is to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of relacorilant relative to healthy matched control male and female subjects (Part 1).
What is the current status of trial NCT06094725?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-01-06. Estimated completion is 2020-12-14.
What conditions does trial NCT06094725 study?
This clinical trial studies the following conditions: Hepatic Impairment.
What interventions are being tested in trial NCT06094725?
The interventions under investigation include: Relacorilant (DRUG).
Who is sponsoring clinical trial NCT06094725?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06094725 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
RECRUITING · Phase 1
-
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
-
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.